178 related articles for article (PubMed ID: 16086873)
1. [Synergetic cytotoxicity of cisplatin and etoposide to leukemia cell line K562 and its mechanism].
Ma WD; Yin MY; Jiang CW; Xu SR; Zhai LD; Zheng LF; Wang YL; Yan YL
Ai Zheng; 2005 Aug; 24(8):958-64. PubMed ID: 16086873
[TBL] [Abstract][Full Text] [Related]
2. [Inhibition of Topo II alpha gene expression and reversing of drug resistance in multi-drug resistant epithelial ovarian cancer cells induced by RNA interference in vitro].
He J; Li L; Tang BJ; Zhang W; Li DR; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2009 Sep; 44(9):686-90. PubMed ID: 20079182
[TBL] [Abstract][Full Text] [Related]
3. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
4. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
[TBL] [Abstract][Full Text] [Related]
5. Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Kawanami K; Nakamura T; Ono M; Kusano T; Okada K; Kikuchi A; Adachi N; Kohno K; Higashi K; Kuwano M
Oncol Res; 1996; 8(5):197-206. PubMed ID: 8884812
[TBL] [Abstract][Full Text] [Related]
6. Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
Zhu FS; Chen XM; Huang ZG; Wang ZR; Zhang DW; Zhang X
J Dig Dis; 2010 Feb; 11(1):34-42. PubMed ID: 20132429
[TBL] [Abstract][Full Text] [Related]
7. Hypophosphorylation of topoisomerase II in etoposide (VP-16)-resistant human leukemia K562 cells associated with reduced levels of beta II protein kinase C.
Ritke MK; Murray NR; Allan WP; Fields AP; Yalowich JC
Mol Pharmacol; 1995 Nov; 48(5):798-805. PubMed ID: 7476909
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of human topoisomerase IIalpha expression correlates with relative amounts of specificity factors Sp1 and Sp3 bound at proximal and distal promoter regions.
Williams AO; Isaacs RJ; Stowell KM
BMC Mol Biol; 2007 May; 8():36. PubMed ID: 17511886
[TBL] [Abstract][Full Text] [Related]
9. Multidrug resistance due to impaired DNA cleavage in a VP-16-resistant human leukemia cell line.
Fukushima T; Takemura H; Yamashita T; Ishisaka T; Inai K; Imamura S; Urasaki Y; Ueda T
Anticancer Res; 1999; 19(6B):5111-5. PubMed ID: 10697518
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells.
Fabian I; Reuveni D; Levitov A; Halperin D; Priel E; Shalit I
Br J Cancer; 2006 Oct; 95(8):1038-46. PubMed ID: 17047652
[TBL] [Abstract][Full Text] [Related]
11. Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.
Zhou Z; Zwelling LA; Ganapathi R; Kleinerman ES
Br J Cancer; 2001 Sep; 85(5):747-51. PubMed ID: 11531262
[TBL] [Abstract][Full Text] [Related]
12. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line.
Reuveni D; Halperin D; Shalit I; Priel E; Fabian I
Int J Oncol; 2010 Aug; 37(2):463-71. PubMed ID: 20596674
[TBL] [Abstract][Full Text] [Related]
13. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
14. Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Minagawa Y; Kigawa J; Irie T; Kanamori Y; Itamochi H; Cheng X; Terakawa N
Jpn J Cancer Res; 1997 Dec; 88(12):1218-23. PubMed ID: 9473741
[TBL] [Abstract][Full Text] [Related]
15. Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.
Xue X; Qu XJ; Gao ZH; Sun CC; Liu HP; Zhao CR; Cheng YN; Lou HX
Invest New Drugs; 2012 Feb; 30(1):212-22. PubMed ID: 20924640
[TBL] [Abstract][Full Text] [Related]
16. [Reverse effect of genetically modified adenovirus H101 on drug-resistance of A549/DDP cells to cisplatin].
Xu RH; Yuan ZY; Guan ZZ; Li S
Ai Zheng; 2005 Aug; 24(8):975-9. PubMed ID: 16086876
[TBL] [Abstract][Full Text] [Related]
17. [Expression of DNA topoisomerases (I, II alpha, II beta) mRNA in etoposide- and mAMSA-resistant cell lines].
Matsumoto Y; Takano H; Nagao S; Iglesias A; Fojo T
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2265-9. PubMed ID: 9422071
[TBL] [Abstract][Full Text] [Related]
18. Genistein inhibition of topoisomerase IIalpha expression participated by Sp1 and Sp3 in HeLa cell.
Zhou N; Yan Y; Li W; Wang Y; Zheng L; Han S; Yan Y; Li Y
Int J Mol Sci; 2009 Jul; 10(7):3255-3268. PubMed ID: 19742137
[TBL] [Abstract][Full Text] [Related]
19. Cellular events involved in the sensitization of etoposide-resistant cells by inhibitors of calcium-calmodulin-dependent processes. Role for effects on apoptosis, DNA cleavable complex, and phosphorylation.
Kawamura K; Grabowski D; Krivacic K; Hidaka H; Ganapathi R
Biochem Pharmacol; 1996 Dec; 52(12):1903-9. PubMed ID: 8951349
[TBL] [Abstract][Full Text] [Related]
20. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides.
Ganapathi R; Constantinou A; Kamath N; Dubyak G; Grabowski D; Krivacic K
Mol Pharmacol; 1996 Aug; 50(2):243-8. PubMed ID: 8700130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
